Telomere Defects Gene Mutation Panel, NGS
Telomeres are short, repetitive segments of DNA composed of TTAGGG nucleotide repeats that protect the ends of chromosomes from abnormally sticking together or breaking down. At birth telomeres length ranges from 8-14 kilobases, however, approximately 50-100 base pairs are lost from telomeres with every cycle of DNA replication. Therefore, with normal aging the average telomere length is decreased such that in centenarians telomeres are only about 4 kb in length. When the telomere length in a cell is reduced below a critical threshold the cell is no longer able to divide and either becomes senescent or undergoes apoptosis.
Unlike the relatively slow rate of division in most somatic cells, cells that undergo frequent division such as epithelium and bone marrow have mechanisms that preserve telomere length and allow prolonged replication. In such cells, telomeres are maintained by two important protein complexes, telomerase and shelterin. Telomerase is an enzyme complex that can extend the length of telomeres by adding small, repeated segments of DNA to the telomere each time the cell divides, thus helping to slow the shortening process. One component of telomerase, called hTR, provides a template for creating the repeated sequence of DNA that telomerase adds to the ends of chromosomes. The dyskerin protein binds to hTR and helps stabilize the telomerase complex. Shelterin is a complex of several proteins (TRF1, TRF2, RAP1, TIN2, TPP1, and POT1) that function to create a stable protein ‘cap’ for the telomere, protecting it from degradation by DNA repair mechanisms.
The genes involved with telomere maintenance and repair may have variants that cause telomeres to shorten more quickly than normal. The diseases associated with telomere defects are: Dyskeratosis congenita, Hoyeraal-Hreidarsson (HH) and Revesz Syndromes, Coats plus syndrome and Idiopathic pulmonary fibrosis.
Dyskeratosis congenital (DC) may be inherited as an autosomal dominant or recessive disorder and is characterized by abnormal skin pigmentation, nail dystrophy, bone marrow failure and oral leukoplakia. Other features that may be present include: epiphora, developmental delay, pulmonary disease, short stature, poor dentition, esophageal stricture, and premature hair. This disorder is caused by mutations in any one of 13 genes (ACD, CTC1, DKC1, NAF1, NHP2, NOP10, PARN, RTEL1, STN1, TERC, TERT, TINF2, WRAP53) that result in dysfunction of the telomerase or shelterin complexes. Cells that divide rapidly are especially vulnerable to the effects of shortened telomeres hence, patients with dyskeratosis congenita experience problems affecting the nail beds, hair follicles, skin, oral mucosa, and bone marrow. Patients with DC are also at increased risk of developing cancers involving these same tissues.
Hoyeraal-Hreidarsson (HH) (due to mutations in ACD, DKC1, PARN, RTEL1 or TINF2) and Revesz Syndromes (TINF2 mutation) are severe forms of DC. HH is characterized by microcephaly, growth and mental retardation, spastic paresis, ataxia and immunodeficiency. Revesz syndrome is characterized by bilateral retinal exudative retinopathy and intracranial calcifications.
Coats plus syndrome is a rare autosomal recessive neurological disorder that overlaps with DC and is caused by mutations in the CTC1 gene. It is characterized by and retinal telangiectasias and exudatates (‘Coats Disease’) plus intercranial calcifications, cerebellar movement disorder, osteopenia, leukodystrophy, poor growth, and bone marrow abnormalities. Individuals with Coats plus syndrome have a mutation in one copy of the CTC1 gene in each cell that eliminates the function of the CTC1 protein and a mutation in the other allele that reduces but does not eliminate the protein's function. This combination of mutations leaves only a small amount of functional CTC1 protein available to work as part of the CST complex. The resulting impairment of this complex affects the replication of telomeres.
Mutations in the TERC gene have been found in 8%-15% of familial idiopathic pulmonary fibrosis (IPF), and germline mutations in TERC are seen in 1%-3% of simplex cases of idiopathic pulmonary fibrosis (IPF). Mutations in TERC can reduce or eliminate the function of telomerase, allowing telomeres to become abnormally short as cells divide. This likely triggers apoptosis or senescence in pulmonary epithelial cells that eventually leads to fibrosis. Mutations in the TERC gene are also associated with an increased risk of various cancers, in particular melanoma and acute myeloid leukemia.
Panel Components
Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: CTC1, DKC1, NHP2, NOP10, LIG4, NAF1, PARN, POT1, RTEL1, TERC, TERT, TINF2, USB1 (C16ORF57), and WRAP53 (TCAB1) associated with telomere defect disorder.
- Helps to provide a comprehensive genetic evaluation for patients with a personal or family history suggestive of telomeropathies
- For the confirmation of a clinical diagnosis of telomeropathy-associated dyskeratosis congenital, Idiopathic pulmonary fibrosis and some cancers
- Identifying pathogenic variants within genes known to be associated with increased risk for telomere defects allowing for predictive testing of at-risk family members
- For the prenatal diagnosis in at-risk pregnancies
- For the appropriate management and surveillance of the disease
Positive
At least one known pathogenic variant or mutation associated with telomeropathies should be detected in the tested genes. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.
Negative
No mutation or pathogenic variant in the tested gene.
Negative for mutation or pathogenic variant in the tested gene
Whole blood, Blood spot, Peripheral blood mononuclear cells (PBMCs), Cultured fibroblasts, Skin biopsy.
Stability (Whole blood)
- Ambient: 3-5 days
- Refrigerated: 7-14 days
Biopsy
- Indefinitely
- Cells. 2019;8: 1406. [PMID: 31717312]
- Pediatr Rep. 2017;9: 7301. [PMID: 29081935]
- Nat Struct Mol Biol. 2015;22: 867-74. [PMID: 26581521]
- Genes Dev. 2013;27: 2099-108. [PMID: 24115768]
- EMBO J. 2012;31: 2309-21. [PMID: 22531781]
- Clin Genet. 2012;81: 470-8. [PMID: 21477109]
- Genet Med. 2010;12: 753-64. [PMID: 21189492]
- Int J Hematol. 2010;92: 419-24. [PMID: 20882440]
- Int J Dent Hyg. 2010;8: 68-74. [PMID: 20096085]
- N Engl J Med. 2007;356: 1317-26. [PMID: 17392301]